Carboplatin (NCT04671667)

Name: Carboplatin trial for Recurrent Head and Neck Squamous Cell Carcinoma (NCT04671667)
Uploaded: 2026-10-31T21:17:59.650Z
Duration: 1 min 23 s
Description: Carboplatin trial for Recurrent Head and Neck Squamous Cell Carcinoma (NCT04671667). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04671667.

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma: a one-minute explainerNCT046716671 min

Carboplatin trial for Recurrent Head and Neck Squamous Cell Carcinoma (NCT04671667). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for people aged 18–79 after removal of recurrent or second-primary mouth, oropharynx, larynx or hypopharynx squamous cancer in a previously irradiated area. Positive margins or extranodal extension, PD-L1 CPS at least one, and no distant spread are required.

The idea: compare pembrolizumab, which supports immune attack, against repeat radiation with cisplatin or carboplatin. Patients are randomized within eight weeks after surgery; pembrolizumab is given intravenously every six weeks for nine cycles.

This phase 2 study plans 188 patients. The National Cancer Institute sponsors it, with 119 recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.